News brief
On 2026-04-28, according to Xiniu Data, Aureka Biotechnologies completed Series A+ financing, raising USD 35 million. Investors were lead investor Hongshan China, Jingwei Venture Capital, Boyuan Capital, Wuyuan Capital and others. The company is a developer of antibody drugs using generative AI.
Connected profiles
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年4月28日，据烯牛数据报道，Aureka Biotechnologies完成A+轮融资，金额3500万美元。投资方为红杉中国领投、经纬创投、博远资本、五源资本等。该公司为人工智能生成式抗体药物开发商。